SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027$10 million milestone payment triggered from licensing agreement ...
Opinion
4dOpinion
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Sanofi is set to pay Lexicon Pharmaceuticals $260 million (€236 million) to get out of a diabetes pact. The dissolution of the alliance follows the generation of mixed clinical data on Zynquista in ...
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Investors might want to bet on Lexicon Pharmaceuticals (LXRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Every investor in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private equity firms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback